Featured News

This month we hear from Sanjith Senthil, one of our younger advocates with a strong dedication to improving the lives of celiac disease patients.

Celiac disease world expert Alessio Fasano, MD, recently wrote a commentary on a study that set out to identify a link between inflammatory bowel disease and celiac disease/celiac autoimmunity in children and adults.   

Looking for something fun to do with your friends and family, no matter where they are across the world? Learn more about the 2023 Turkey Trot 5k and how joining or creating a team can expand your fundraising and accelerate celiac disease research for treatment and a cure. 

The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions.

At CDF, we deeply value hearing stories from our patient community. Your stories are a pivotal part of our efforts to build awareness and fight for research funding. 

The Celiac Disease Foundation is proud to continue our partnership with the Celiac Disease Center at Columbia University in presenting an annual free livestream international symposium, this year titled “Celiac Disease: On the Horizon”. Recording available now.

An international study exploring the molecular characteristics of celiac disease identified several genes highly associated with the disease. This new study uncovered that these genes play a pivotal role in regulating celiac disease’s immune response.

Each month in our advocacy newsletter, the Celiac Disease Foundation highlights one of our many dedicated advocates as part of our Patient Profile Series.

The ACeD-it Study is looking for adult volunteers with celiac disease to join a phase 1b/2 clinical trial. Your participation could make a difference.

The Celiac Disease Foundation, is proud to announce a recent grant of $200,000 from the Foster Family Foundation, which CDF will use to further its mission.